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Introduction
After breast-conserving surgery, radiotherapy (RT) plays 
an essential role to reduce local recurrences in the residual 
breast and to improve cancer-specific and overall survival (1). 
Recent studies concentrated on tailoring RT to the patient’s 
individual risk according to pathological and bio-molecular 
prognostic factors, in order to reduce the volume and the 
duration of complementary RT in selected patients (2-4). 
In fact, irradiation of a smaller volume, i.e., the tumour bed 
with a safety margin, allows an increase of the daily dose by 
hypofractionation without increasing the risk of late toxicity. 
The concept and the role of partial breast irradiation (PBI) 
were recently analyzed in three prospective randomized 
clinical studies using brachytherapy or intraoperative 
radiation therapy (IORT) (5-7). 
The rationale for PBI is that, in the large majority of the 
cases, ipsilateral breast cancers recurrences occur close to 
the site of lumpectomy. From the historical trials, the risk 
of breast cancer recurrence outside index quadrant without 
breast irradiation is in the range of 1.5–3.5% (8,9). PBI 
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can be delivered over 1 day to 2 weeks, depending on the 
technique, i.e., IORT, interstitial brachytherapy, or external 
beam RT. The IORT represents a very convenient PBI 
modality since it does not require any further radiation 
treatment for the patients after the surgical procedure and 
reduces the workload of the RT department.
The main challenge of PBI is the appropriate patient 
selection. Upon literature data, European and American 
Societies of Radiation Oncology (GEC-ESTRO, ASTRO) 
published consensus statements regarding these criteria 
(10,11). According to these documents, the most suitable 
patients for PBI are older than 60 years with invasive 
ductal cancer, unicentric T1 lesion, positive oestrogen 
receptor status, absence of lymph vascular space invasion 
and negative surgical margins (10,11). Multifocal and 
multicentric lesions are exclusion criteria for PBI because of 
the high risk of tumour relapse in the other quadrants. With 
this perspective, the use of the most appropriate diagnostic 
imaging is a key point for patient selection to identify small 
unicentric lesions.
In this regard, a recent publication by Tallet et al. (12) 
explored the impact of preoperative magnetic resonance 
imaging (MRI) on patient eligibility for PBI by IORT. One 
hundred 75 patients meeting the international selection 
criteria were planned for surgery with IORT. Seventy-
nine percent of them underwent breast MRI as part of the 
preoperative assessment. The reasons for not undergoing 
MRI were surgeon’s opinion, MRI contraindication, and 
patient’s refusal. The supplemental foci defined as ACR3-4 
(ACR3 = probably benign, ACR4 = suspicious) underwent 
a second ultrasound, and if the suspicious was confirmed 
patients underwent biopsy. The supplemental foci defined 
as ACR5 (ACR5 = cancer) were immediately submitted to 
biopsy. Ipsilateral suspicious lesions were identified in 33 
patients (23%) and 21 (15%) underwent a biopsy. A second 
ipsilateral tumour was detected in 4% of the patients with 
a change of treatment strategy. Moreover, a contralateral 
breast cancer was found in 4.3% of the patients. In the 
conclusion, the authors propose the routine use of MRI for 
the staging of patients who are candidates for PBI. 
This concept can be applied to any PBI modality but 
it is more crucial for PBI with IORT when no additional 
imaging procedure is done to identify the radiation target. 
In relation with the Tallet’s article, we analyzed and 
discussed the use of MRI for the identification of the 
patients who could benefit the most from PBI, especially 
using IORT. 
MRI and other imaging modalities
Conventional MRI by T1 (with contrast)  and T2 
weighted images has a superior sensitivity compared 
to mammography in detecting ipsilateral multifocal 
or multicentric breast cancers (13). The sensitivity for 
detection of invasive cancer is reported up to 100%. The 
advantage of MRI has been shown to be non-significant 
in fatty breasts, while significant in fibro glandular and 
heterogeneous or very dense breasts (14-16). However, 
MRI with conventional sequences is limited in the detection 
of pre-invasive lesions (i.e., in situ ductal cancer), because 
it is unable to detect micro calcifications. In such a case, 
sensitivity is between 60% and 90% (17).
Some authors analyzed the role of MRI in PBI setting 
and found that 5–10% of the patients initially considered 
for PBI resulted unsuitable because of MRI findings (18-21). 
Houssami et al. (22) analyzed 19 studies and observed that 
MRI can detect additional disease in the affected breast in 
the 16% of women with breast cancer, while 66% of these 
findings are confirmed as malignant at histology, during 
surgery or biopsy. In women with multicentric neoplastic 
foci, the meta-analysis showed that conversion from 
lumpectomy to mastectomy, according to MRI findings, 
occurred in 11.3% of cases. 
The clinical significance of detecting these additional 
sites of disease was reported by a German group 
in a retrospective review of 346 patients who were 
preoperatively staged with (n=121) or without (n=225) 
MRI (23). At a mean follow-up of 40 months, the in-breast 
tumour recurrence rate in patients treated with breast 
conservative therapy and staged with MRI was 1.2% (1/86) 
compared with 6.5% (9/138) of the patients staged without 
preoperative MRI (P<0.001). The authors underlined 
that some in-breast recurrences appear to correlate with 
cancer that was already present at the time of diagnosis. In 
the German study, all new foci underwent a biopsy with 
a negative result in 61.2% of cases (23). Such a procedure 
could be considered invasive and stressful for patients and 
resulted worthless in 61% of them. 
In this regard, the study by Tallet et al. (12) adopted a 
less invasive approach for managing the MRI false positive 
foci: after positive (ACR3-4) preoperative breast MRI, 
all patients were subsequently studied with a second look 
ultrasound, and only the confirmed ultrasound suspicious 
foci underwent fine needle biopsy. 
In the era of justification of every single procedure, any 
diagnostic process should be justified in terms of indication 
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and optimized in terms of potential risks for patients. The 
concept of “optimization” in diagnosis is well described for 
the use of ionizing radiations by the EURATOM Directives 
using the “ALARA” principle: the radiation dose should be 
kept at the level as low as reasonably achievable taking into 
account social and economic factors.
This definition, by analogy, could be applied also for 
other diagnostic modalities not using ionizing radiations 
but having potential risks for the patients and costs for the 
society. By applying this concept, the use of breast MRI 
could be limited because it is a time-consuming technique; 
its availability is limited and costly. On the other hand, its 
use could be justified by the potential benefits. A possible 
clinical scenario could be the implementation of MRI 
in a subgroup of patients at higher risk. With regard to 
this concept, a multidisciplinary working group included 
preoperative MRI as a recommendation for PBI (24). Upon 
the available literature data, this panel estimated that about 
5–10% of patients eligible at standard assessment would be 
ineligible after MRI imaging. In this regard, a recent meta-
analysis by Di Leo et al. (25) reviewed the articles analyzing 
the ineligibility for PBI after MRI. Out of 3,136 patients, 
11% of initially eligible for PBI resulted ineligible after 
MRI. Of interest, the authors observed as predicting factors 
of ineligibility after MRI: the invasive tumours at stage pT2 
or higher, the invasive lobular histology pattern and the 
premenopausal status. In the single institution retrospective 
study by Tallet et al. (12), the authors used the eligibility 
criteria proposed by the ESTRO guidelines. With strict 
adherence to them, they observed a lower incidence of 
second ipsilateral cancer (4%) compared to the Di Leo’s 
data. 
The challenge of the occult additional lesions detected 
by MRI is the real clinical implication, and it is not clear 
if these lesions could be indolent or aggressive lesions. In 
the literature, there are a few studies trying to predict the 
aggressiveness of the tumour foci by using the apparent 
diffusion coefficient (ADC) value of diffusion weighted 
(DW)-MRI and the standardized uptake value (SUV) 
of the [18F]FDG-PET. In a sample of 70 breast cancer 
patients, Karan et al. found that the median ADC value was 
significantly associated with vascular invasion (P=0.008). 
The maximum SUV (SUVmax) was also significantly 
correlated with tumour size (P=0.001), histological grade 
(P=0.001), lymph node status (P=0.0015), oestrogen 
receptor status (P=0.010), and human epidermal growth 
factor receptor 2 status (P=0.020) (26). With a similar 
purpose, Molinari et al. observed that lower ADC values 
are associated with elevated Ki67 proliferation index in 
115 breast cancer lesions (27). The association of ADC and 
Ki67, that could be considered a marker of aggressiveness, 
may help for understanding also the clinical value of occult 
foci detected by MRI. On the other hand, Soussan et al. 
evaluated the association of Ki67 with PET SUVmax in a 
limited number of patients. By 41 breast cancer, SUVmax 
was positively correlated with Ki-67 (P<0.0004) and triple 
negative breast cancer (P=0.004) (28).
Considering these sequences, Fusco et al. evaluated if 
dynamic contrast enhanced (DCE)-MRI with DW-MRI in 
31 suspicious breast lesions (15 malignant and 16 benign 
proved by histological examination) could increase the 
diagnostic power. The combination of DCE and DW-MRI 
did not improve the sensitivity and specificity observed if 
DCE and DW-MRI were considered separately (29).
In a meta-analysis of 19 studies on the diagnostic 
performance of proton MRI spectroscopy for the 
differentiation between malignant and benign breast 
lesions, the pooled overall sensitivity and specificity were 
73% and 88%, respectively (30). Spectroscopy seems to be 
highly specific for identifying tumours diameter, multifocal 
and multicentric disease and in situ breast cancer, however 
further systematic researches are necessary to verify its 
diagnostic value. 
Of potential interest is also the application of the 
integrated positron emission tomography (PET)/
MRI. Kong et  al .  analyzed a sample of 42 [18F]-
Fluorodeoxyglucose (18F-FDG)-PET/MRI studies 
and achieved a sensibility of 87.5% in detecting breast 
cancer lesion compared to a PET imaging that achieved 
a sensibility of 79%. The limit of this approach is the low 
number of centre equipped with this diagnostic tool (31). 
The use of these imaging modalities other than 
conventional MRI, when validated by solid clinical studies, 
could add useful information and could represent in the 
future an alternative to the use of conventional MRI.
Current studies and future perspectives
In the study by Tallet et al. (12), MRI was part of the 
preoperative staging in the 79% of patients considered for 
PBI with IORT. On the other hand, the randomized trials 
on IORT PBI did not include MRI as a part of standard 
staging mainly because their study design was made before 
more recent knowledges. Only in the TARGIT trial, MRI 
was performed in 5.6% of the patients. 
To our knowledge, most of the ongoing randomized 
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or single arm clinical trials on PBI do not systematically 
includes MRI for the patient staging.
The prospective single arm ongoing TARGIT-Elderly 
trial (NCT01299987) is performing IORT in verified 
early invasive cancer for patients aged >70 years, and 
does not require breast MRI for staging (32). In such a 
setting, it could be considered appropriate the only use of 
a standard staging because breast density has a less impact 
in elderly patients. The single arm ongoing TARGIT-C 
(consolidation) study should confirm the efficacy of a single 
dose of IORT in a well selected group of patients older than 
50 years with small breast cancer and absence of risk factors; 
also in this trial, MRI is not considering an inclusion 
criterion (33).
The National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-39/Radiation Therapy Oncology 
Group (RTOG) 0413 study is a randomized phase III trial 
comparing conventional breast RT and PBI with different 
techniques for women older than 50 years with stage 0, I, or 
II breast cancer. Also in this trial, MRI is not considered as 
a staging procedure (34).
Other ongoing studies on PBI include preoperative 
MRI for patient selection. A pilot study of the Chicago 
University (35) aiming at determining if PBI following 
lumpectomy in patients screened with MRI provides 
similar rates of local failure, limited acute skin toxicity, late 
complications and cosmetic outcome when compared to 
historical rates of toxicity of patients treated with standard 
whole breast RT. 
Another study (36) currently recruiting, on the use of 
CyberKnife for PBI, includes breast MRI when there is a 
suspicion of multicentric disease. The additional suspicious 
areas will require a positive biopsy before changing 
treatment approach. 
In a quite different setting, a phase II RTOG study of 
repeat breast preserving surgery and 3D-conformal partial 
breast re-irradiation for local recurrent breast carcinoma (37) 
performs a bilateral breast mammogram and bilateral breast 
MRI within 120 days prior to study entry. 
In conclusion, literature data including the Tallet’s study 
show that MRI is able to detect lesions outside the target 
volume of RT in about 4% of the patients’ candidates to 
IORT. Other literature data support the use of MRI for the 
PBI selection criteria (24) although the GEC-ESTRO and 
ASTRO guidelines do not recommend the routinely use of 
MRI to select patients for PBI.
The magnitude of the gain by MRI in the setting of PBI 
is a worthy issue deserving further investigation, preferably 
in the setting of prospective clinical trials. The most 
conclusive approach would be a study randomizing patients 
who undergo or not MRI before PBI. 
Until more long-term and solid data looking at cost-
effectiveness and clinical outcomes will be available, the use 
of preoperative MRI in PBI candidates may be performed 
in patients with mammographically dense breasts or with 
discrepancies between mammography and ultrasound and 
second look with ultrasound, as proposed by Tallet et al. (12). 
Moreover, clinical and biological factors as well could help 
to identify patients with high risk of multicentric lesions 
who could benefit the most from MRI. 
Upon these considerations, MRI can be a very powerful 
and useful tool to optimize patient selection for PBI 
but its use outside clinical trials should be discussed in 
multidisciplinary setting in order to balance costs and 
benefits for each single patient. 
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